20 Years Later, Did the Digital Market Save African Farmers?
12 It started in the days when the mobile phone was one of the greatest things to happen to Africa. The neighbours came …
Antobot scales UV-C robotics push with 300 deployments targeted in 2027
UK-based startup Antobot is aiming to deploy 300 autonomous robots in strawberry crops next year as more growers become …
IFF taps water-based perfume trend with Aquascent fine fragrance carrier
International Flavors & Fragrances (IFF) has introduced Aquascent, a vegan, water-based carrier for fine fragrance. The new solution is made from a proprietary formula made with biodegradable materials.
Amplio’s Phase 1b data hint at better first-line arthritis treatment
Methotrexate is an established drug that reduces inflammation and helps slow joint damage in rheumatoid arthritis, an autoimmune disease in which the immune system attacks the joints. Its effectiveness, long clinical track record and low cost make it the standard first-line treatment.
FBN and Google team up to give farm AI the context it’s been missing
Farmers Business Network (FBN) Google’s AI Futures Fund (AIFF) announced a partnership this week to build an ̶…
L’Oréal puts social commerce first with Dr.G US launch on TikTok Shop
Dr.G has landed on TikTok Shop, accelerating the brand’s US expansion. The launch follows L’Oréal’s acquisition of Dr.G in 2024 and comes as the company continues to invest in the growing K-beauty category globally. According to the brand, global K-beauty value sales are up 53% year-over-year.
GSK adds liver candidate from Wave RNA partnership
Why it matters: The decision shows that the companies’ RNA drug discovery alliance continues to deliver candidates, despite GSK relinquishing rights to Wave’s lead RNA editing therapy earlier this year. It also adds to GSK’s work in liver disease, where its own small interfering RNA (siRNA) candidate gatuzosiran is already in Phase 2 development.
Highlight Therapeutics’ skin cancer injections show promise in Phase 2b
Why it matters: Highlight is developing the injected immunotherapy as a potential alternative to surgery, particularly for tumors on the face and neck. Surgery remains the most common treatment, but removing tumors in these sensitive areas can leave scars and require reconstruction.
September in review: BASF eyes Evonik, EU Green Transition Directive, GLP-1 and beauty
In September, BASF confirmed takeover talks with Evonik, a deal that could consolidate two of Europe’s largest beauty suppliers.
Boehringer, Zealand obesity drug face tolerability questions after Phase 3 success
Why it matters: The results strengthen the evidence for the Zealand Pharma-originated drug in a population where weight loss is typically harder to achieve. However, its efficacy faces strong competition from existing treatments, while the discontinuation rate raises questions about how many patients could sustain treatment.
